Celon Pharma S.A. (WSE:CLN)

Celon Pharma Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	22.37	26.85	32.36	82.9	147.8	43.98
Short-Term Investments	16.61	48.24	82.18	81.72	79.76	-
Cash & Short-Term Investments	38.98	75.09	114.54	164.62	227.55	43.98
Cash Growth	-67.81%	-34.45%	-30.42%	-27.65%	417.42%	-34.06%
Accounts Receivable	39.43	39.26	32.79	27.11	24.67	32.53
Other Receivables	11.02	12.72	15.45	6.59	2.57	9.49
Receivables	50.45	51.99	48.24	33.7	27.25	42.02
Inventory	27.34	30.17	26.41	38.39	23.38	29.76
Other Current Assets	4.15	3.18	0.56	0.87	0.53	3.48
Total Current Assets	120.92	160.43	189.75	237.58	278.7	119.24
Property, Plant & Equipment	303.74	311.66	333.8	341.59	316.57	313.8
Long-Term Investments	15.49	32.56	11.26	13.25	38.12	12.87
Other Intangible Assets	2.92	8.15	14.29	21.15	27.81	38.38
Long-Term Deferred Tax Assets	11.86	21.55	19.05	28.14	31.94	27.17
Long-Term Deferred Charges	-	-	0.68	0.68	1.36	2.72
Other Long-Term Assets	21.74	9.46	0.47	0.38	12.64	17.7
Total Assets	482.63	543.8	569.31	642.76	707.14	531.89
Accounts Payable	14.78	15.43	10.51	17.47	11.87	18.42
Accrued Expenses	10.47	8.1	7.39	6.8	3.11	6.77
Short-Term Debt	4.24	1.53	12.75	-	-	12.84
Current Portion of Leases	8.01	7.14	7.13	19.43	6.56	3.49
Current Unearned Revenue	15.7	17.92	31.09	56.42	55.83	45.78
Other Current Liabilities	14.58	16.78	17.48	16.32	8.99	26.86
Total Current Liabilities	67.78	66.9	86.34	116.44	86.36	114.15
Long-Term Leases	7.62	8.26	5.71	7.39	8.35	9.16
Long-Term Unearned Revenue	21.11	20.22	22.88	25.62	29.85	39.67
Long-Term Deferred Tax Liabilities	0.34	2.85	3.01	1.32	6.04	-
Other Long-Term Liabilities	0.67	0.36	5.81	12.35	22.53	24.38
Total Liabilities	97.52	98.59	123.75	163.12	153.14	187.36
Common Stock	5.39	5.39	5.11	5.1	5.1	4.5
Additional Paid-In Capital	516.81	551.25	543.23	587.1	613.51	393.12
Retained Earnings	-138.67	-114.96	-108.64	-119.79	-91.67	-58.57
Comprehensive Income & Other	1.59	3.53	5.85	7.23	27.07	5.48
Shareholders' Equity	385.11	445.21	445.56	479.65	554	344.53
Total Liabilities & Equity	482.63	543.8	569.31	642.76	707.14	531.89
Total Debt	19.88	16.93	25.59	26.82	14.92	25.48
Net Cash (Debt)	19.1	58.16	88.95	137.8	212.63	18.5
Net Cash Growth	-81.95%	-34.62%	-35.45%	-35.19%	1049.56%	-71.56%
Net Cash Per Share	0.36	1.11	1.74	2.70	4.55	0.41
Filing Date Shares Outstanding	53.86	53.86	51.06	51.04	51	45
Total Common Shares Outstanding	53.86	53.86	51.06	51.04	51	45
Working Capital	53.14	93.53	103.41	121.14	192.34	5.1
Book Value Per Share	7.15	8.27	8.73	9.40	10.86	7.66
Tangible Book Value	382.19	437.06	431.26	458.5	526.19	306.16
Tangible Book Value Per Share	7.10	8.12	8.45	8.98	10.32	6.80
Land	6.35	6.35	6.35	6.35	6.35	6.35
Buildings	157.97	157.97	146.4	146.35	146.08	173.5
Machinery	242.92	317.71	272.86	190.43	177.34	164.34
Construction In Progress	17.53	15.75	79.95	74.3	50.63	31.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.